Protagenic Therapeutics, Inc. (PTIX)

NASDAQ: PTIX · IEX Real-Time Price · USD
0.520
-0.010 (-1.87%)
Dec 5, 2022 4:30 PM EST - Market closed
-1.87%
Market Cap 9.16M
Revenue (ttm) n/a
Net Income (ttm) -3.84M
Shares Out 17.29M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,072
Open 0.52
Previous Close 0.53
Day's Range 0.52 - 0.548
52-Week Range 0.52 - 1.885
Beta -0.09
Analysts Buy
Price Target 4.08 (+684.5%)
Earnings Date Nov 15, 2022

About PTIX

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York. [Read more]

Industry Biotechnology
IPO Date Jan 5, 2016
Employees 1
Stock Exchange NASDAQ
Ticker Symbol PTIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for PTIX stock is "Buy." The 12-month stock price forecast is 4.08, which is an increase of 684.46% from the latest price.

Price Target
$4.08
(684.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on ...

NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic diso...

7 months ago - Accesswire

Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update

NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today a...

1 year ago - GlobeNewsWire

Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET

Scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and A ddiction to be discussed

1 year ago - GlobeNewsWire

Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update

NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today a...

1 year ago - GlobeNewsWire

Protagenic Therapeutics To Start Clinical Trials For Depression Candidate By 2021 End

Upon reviewing Protagenic Therapeutics Inc's (NASDAQ: PTIX) Investigational New Drug (IND) application for its lead compound, PT00114, the FDA has currently rejected the Company's IND. The application s...

1 year ago - Benzinga

Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial

NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today a...

1 year ago - GlobeNewsWire

Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at...

NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today a...

1 year ago - GlobeNewsWire

7 Best Penny Stocks to Buy Now for Potential 10X Gains

Penny stocks offer a lot of risk balanced by lots of reward. Here are 7 that could surge in price and which have reasonable catalysts behind them.

1 year ago - InvestorPlace

Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on...

NEW YORK , June 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a bioharmaceutical company focused on developing drug product candidates to treat stress-related neurologic diso...

1 year ago - GlobeNewsWire

Market Update: The 10 Most Volatile Stocks Today

Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day. The post Market Update: The 10 Most Volatile Stocks Today appeared first on In...

1 year ago - InvestorPlace

Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq

New York, April 29, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the closing of an underwritten public offering of 3,180,000 units at a publ...

1 year ago - GlobeNewsWire

Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering

New York, April 26, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the pricing of an underwritten public offering of 3,180,000 units at a publ...

1 year ago - GlobeNewsWire